Aims of the Committee

To study the possibility of the establishment of an IAC Foundation

Specific Topics

  • Shorter term: Allocate a percentage of the annual IAC budget specifically for philanthropy/ charitable giving and determine what initiatives will be funded (bursaries, mentorship, advocacy).
  • Longer term: determine the logistics, feasibility, and need to establish an IAC Foundation (Legal considerations, tax deduction implications for global donors, etc.)

Chair: Martha Pitman
Deputy-Chair: Claire Bourgain
Members: Andrew Field, Syed Ali
Members ex-officio: Massimo Bongiovanni and Fernando Schmitt


Dr. Martha Pitman, MIAC

Dr. Pitman is Professor of Pathology at Harvard Medical School and practising pathologist in cytopathology and gastrointestinal surgical pathology at Massachusetts General Hospital.
She has been Associate Editor of Cancer Cytopathology and The Journal of the American Society of Cytopathology and is currently active on the editorial boards of several journals. She is the lead author of the PSC Pancreaticobiliary Terminology System for reporting pancreaticobiliary cytology as well as the new WHO Reporting System for Pancreaticobiliary Cytology. She is also on the Standing Committee (one of 5 series editors) for all WHO Reporting Systems.


Dr Claire Bourgain, MIAC

Dr. Bourgain is Head of the Department of Pathology at Imelda Hospital, Bonheiden, Leuven, Belgium.


dr. Syed Z. Ali, MD, FRCPath, FIAC

Dr. Ali serves as Professor of Pathology and Radiology at the Johns Hopkins University School of Medicine as well as the Director of the Division of Cytopathology at The Johns Hopkins Hospital. He received his Pathology residency training at North Shore University Hospital in New York with fellowships in Surgical Pathology at the Memorial Sloan-Kettering Cancer Center in New York City and Cytopathology at The Johns Hopkins Hospital in Baltimore.

Andrew Field, MB BS (Hons), FRCPA, FIAC

Dr. Field is head of the Department of Anatomical Pathology at St Vincent’s Hospital, Sydney, and Associate Professor at the University of New South Wales and Notre Dame University Medical Schools. He is currently the President of the International Academy of Cytology and a foundation member of African Strategies for Advancing Pathology, an organization that aims to advocate for and coordinate improvements in pathology services throughout Africa.

Ex-Officio Members

Dr. Massimo Bongiovanni, FIAC

Massimo Bongiovanni, MD, FIAC

Dr. Bongiovanni is head of Cytopathology at SYNLAB Pathology in Lausanne, Switzerland. He is member of the Pathology Expert Group, at SYNLAB International, Member (MIAC) and then Fellow (FIAC) of the International Academy of Cytology since 2016. He is the author of more than 200 scientific articles and 15 book chapters. He was Vice President of the Swiss Cytology Society (2015-2021) and a member of the Endocrine Tumor Group of the European Organisation for Research and Treatment of Cancer (EORTC). He is associate editor of the journal Acta Cytologica and participates in the editorial board of the journal Diagnostic Cytopathology. He is currently co-chair of the scientific committee of the European Federation of Cytology Societies (EFCS).

Prof. Fernando Schmitt, FIAC


Fernando Schmitt is a Professor of Pathology at the Medical Faculty of University of Porto, Senior Researcher and Head of Molecular Pathology Unit at IPATIMUP, Director of RISE (Clinical and Transnational Research Network of the Medical Faculty), Past-President of the International Society of Breast Pathology and President of the International Academy of Cytology (IAC). His research work is on breast cancer, with emphasis on molecular markers, cell adhesion and invasion, therapeutic targets, and mechanisms of resistance. In the last years, his research work has been dedicated to the study of molecular markers on cytological material. Fernando serves as Editor in Chief of Pathobiology and Associate Editor of six major scientific journals and sits on the editorial board of many others. He is a standing member of the WHO-IAC Classification of Tumours.